Bacitracin

D06A - Antibiotics for dermatological use ATC D06AX05 Protein approved 1948 Parenteral Topical Natural product Black-box warning

JFDA label: BANEOCIN Powder

⚠ Black-Box Warning

nephrotoxicity — ChEMBL drug_warning (Black Box Warning) | United States

Mechanism of Action

Inhibitor of C55-isoprenyl pyrophosphate — C55-isoprenyl pyrophosphate inhibitor

Target	Action	Gene / class
C55-isoprenyl pyrophosphate efficacy	INHIBITOR

Indications

Approved

Bacterial Infections — bacterial disease
Burns — burn
Eye Infections — eye infection
Infections — infection
Pneumonia — pneumonia

Off-label

Arrhythmias, Cardiac
Paranasal Sinus Diseases

Dosing

Source: openFDA

Directions unscrew cap and pull tab to remove foil seal adults and children 2 years of age and older: clean the affected area apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily may be covered with a sterile bandage children under 2 years of age: ask a doctor

Warnings & Precautions

Source: openFDA

Warnings & Precautions

Warnings For external use only Do not use if you are allergic to any of the ingredients Ask a doctor before use if you have deep or puncture wounds animal bites serious burns When using this product do not use in the eyes do not apply over large areas of the body Stop use and ask a doctor if you need to use for more than 1 week condition persists or gets worse symptoms persist for more than 1 week or clear up and occur again within a few days rash or other allergic reaction develops Keep out of reach of children. If swallowed get medical help or contact a Poison Control Center right away

Pregnancy & Lactation

Pregnancy

Lactation

Compatible Hale L1

Because it is poorly absorbed after topical application and oral ingestion, bacitracin is considered a low risk to the nursing infant. Only water-miscible cream or gel products should be applied to the breast because ointments may expose the infan...

Chemistry & Properties

Formula	C66H103N17O16S
Molecular weight	1422.72 g/mol
IUPAC name	(4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
CAS	1405-87-4
PubChem CID	10909430
InChIKey	`CLKOFPXJLQSYAH-ABRJDSQDSA-N`

SMILES

CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability	70.0%
Half-life	2.342 h
Volume of distribution	0.284 L/kg
Protein binding	35.5%
BBB penetrant	No

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Drug–drug interactions (68, DDInter)

Interacting drug	Severity	Management
Amikacin	major
Amikacin (liposome)	major
Cidofovir	major
Deferasirox	major
Diatrizoate	major
Everolimus	major
Gentamicin	major
Human Rho(D) immune globulin	major
Human botulinum neurotoxin A/B immune globulin	major
Human cytomegalovirus immune globulin	major
Human immunoglobulin G (intravenous and subcutaneous)	major
Human immunoglobulin G (intravenous)	major
Inotersen	major
Iodipamide	major
Iodixanol	major
Iohexol	major
Iopamidol	major
Iopromide	major
Iothalamic acid	major
Ioversol	major
Ioxilan	major
Kanamycin	major
Neomycin	major
Netilmicin	major
Plazomicin	major
Sirolimus	major
Streptomycin	major
Tacrolimus	major
Temsirolimus	major
Tobramycin	major
Typhoid vaccine (live)	major
Vibrio cholerae CVD 103-HgR strain live antigen (live)	major
Atracurium	moderate
Balsalazide	moderate
Capreomycin	moderate
Cisatracurium	moderate
Clofarabine	moderate
Doxacurium	moderate
Entecavir	moderate
Estradiol	moderate

Showing 40 of 68.

Registered Products (9)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
Cicatrin Cream	Cream 3300 IU, 250 IU	15 g tube	Suleiman Tannous & Sons Co. Ltd	0.740
NEOBACIN SKIN OINT.	Ointment (as Neomycin Sulfate)5 mg, (as Bacitrain Zinc)250 IU	15 g tube	Dar Al Dawa Development and Investment Co Ltd/Jordan	0.810
Cicatrin Powder	Powder 3300 IU, 250 IU	15 g	Suleiman Tannous & Sons Co. Ltd	0.830
multicin Z center oint.	Ointment 3.5 mg, 5000 IU, 400 IU	15 g tube pack varies	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	0.970
BANEOCIN Powder	Powder 250 IU, 5000 IU	10 g	Nabulsi Drug Store	1.040
multicin z center powder	Powder (as Sulphate)3.5 mg/g, (as Sulphate)5000 IU/g, (as zinc)400 IU/g	15 g	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	1.560
BANEOCIN OINT	Ointment 250 IU/g, 5000 IU/g	20 g tube	Nabulsi Drug Store	1.600
multicin Z center oint.	Ointment 3.5 mg, 5000 IU, 400 IU	30 g tube pack varies	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	1.840
Multisol Aerosol 150 gm	Cream 500.000 IU, 150.000 IU, 40.000 IU	150 gm	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	7.320